Jason White

Prof Jason White

School of Pharmacy and Biomedical Science

College of Health

Jason White is an Adjunct Professor in the School of Pharmacy and Medical Sciences, University of South Australia. He qualified from the University of Adelaide with a BSc (Hons) and a PhD, received post-doctoral training in pharmacology at Emory University and subsequently held academic positions at Monash University, the University of Adelaide and at the University of South Australia from 2010 to 2018 as Professor of Pharmacology and Head of the School of Pharmacy and Medical Sciences. Prof White has published extensively in the pharmacology of addictive drugs and in the treatment of drug and alcohol dependence, and attracted numerous research grants and contracts from NHMRC, NIH, government and industry. In addition to research and teaching, he has extensive experience in the treatment of people with alcohol and drug problems, in the management of clinics providing such treatment, and in the provision of expert evidence related to drug effects in civil and criminal matters. He is currently Chair of the World Health Organization Expert Committee on Drug Dependence.

My research focuses on the pharmacology of drugs of dependence, particularly opioids and stimulants. We have a laboratory to measure physiological, behavioural and cognitive function in human subjects, both volunteers and clinical populations. The clinical groups include people being treated for drug dependence and pain patients who are prescribed opioids. We also conduct clinical trials in these populations at treatment centres in Adelaide.Our research has two main aims. The first is to characterise the adverse effects of long term use of opioids and stimulant drugs. For example, we have shown that prolonged opioid use in the context of either pain treatment or addiction increases sensitivity to some types of painful stimuli. This opioid-induced hyperalgesia may play an important role in maintaining long term patterns of opioid use. In future research we will examining the factors that predict the degree of hyperalgesia (eg pharmacogenetic factors) and pharmacological strategies to reduce hyperalgesia. Another project involves collaboration with cognitive psychologists to characterise the impairment in function arising from chronic opioid use and the relative effects of partial and full agonists. The second aim is to improve current treatments for drug dependence and pain. Several strategies are being used. One is to improve medication adherence and reduce the variation due to pharmacokinetics by using long acting formulations of drugs currently employed in treatment. For example, we conducted the first trial of a buprenorphine implant that provided therapeutic concentrations of the drug over a 6 month period. A second strategy has been to trial novel drug combinations. For example, we showed the efficacy of combinations of buprenorphine with ultra-low doses of opioid antagonists. This was the first definitive study to demonstrate that a combination shown in animal models to reduce opioid requirements and decrease the development of tolerance was also effective in humans. We have also used pharmacogenetic approaches to examine how opioids can best be used to minimise risks of dependence.

Year Citation
2025 Keller, E. L., Peake, B., Simpson, B. S., White, J. M., & Gerber, C. (2025). Comprehensive method to detect nitazene analogues and xylazine in wastewater. Environmental Science and Pollution Research, online, 1-8.
DOI Scopus3
2025 Keller, E. L., Peake, B., Simpson, B. S., Longo, M., Trobbiani, S., White, J. M., & Gerber, C. (2025). Searching for a needle in a haystack: chemical analysis reveals nitazenes found in drug paraphernalia residues. Drug and Alcohol Review, 45(1), 1-6.
DOI Scopus1 Europe PMC1
2025 Nielsen, S., Silva, J. P., Jones, J. D., Krotulski, A., Poovendran, D., Muzangizi, D., . . . Comer, S. D. (2025). Behavioural effects and Naloxone effectiveness With new synthetic opioids. Drug And Alcohol Review, online(1), 1-14.
DOI
2024 Jaunay, E. L., Simpson, B. S., White, J. M., & Gerber, C. (2024). Amphetamine-type drug-related fatalities in the context of 8 years of methamphetamine use measured by wastewater analysis in South Australia. Drug Testing and Analysis, 16(10), 1137-1143.
DOI
2024 Tscharke, B., Livingston, M., O'Brien, J. W., Bade, R., Thomas, K. V., Mueller, J. F., . . . Thai, P. K. (2024). Seven-years of alcohol consumption in Australia by wastewater analysis: exploring patterns by remoteness and socioeconomic factors. Drug and Alcohol Dependence, 259(111317), 1-5.
DOI Scopus6 WoS8 Europe PMC5
2024 Jaunay, E. L., Bade, R., Paxton, K. R., Nadarajan, D., Barry, D. C., Zhai, Y., . . . Gerber, C. (2024). Monitoring the use of novel psychoactive substances in Australia by wastewater-based epidemiology. Science of the Total Environment, 919(170473), 7 pages.
DOI Scopus17 WoS14 Europe PMC12
2023 Tscharke, B. J., O'Brien, J. W., Ahmed, F., Nguyen, L., Ghetia, M., Chan, G., . . . Hall, W. (2023). A wastewater-based evaluation of the effectiveness of codeine control measures in Australia. Addiction, 118(3), 480-488.
DOI Scopus8 WoS7 Europe PMC5
2023 Thai, P. K., Tscharke, B. J., O'Brien, J., Gartner, C., Bade, R., Gerber, C., . . . Mueller, J. F. (2023). Increased nicotine consumption in Australia during the first months of the COVID-19 Pandemic. Nicotine & Tobacco Research, 25(6), 1194-11197.
DOI Scopus4 WoS4 Europe PMC2
2023 Jaunay, E. L., Simpson, B. S., White, J. M., & Gerber, C. (2023). Using wastewater-based epidemiology to evaluate the relative scale of use of opioids. Science of the Total Environment, 897(165148), 1-7.
DOI Scopus7 WoS7 Europe PMC5
2023 Bade, R., Rousis, N., Adhikari, S., Baduel, C., Gerber, C., Jaunay, E., . . . Mueller, J. F. (2023). Three years of wastewater surveillance for new psychoactive substances from 16 countries. Water Research X, 19(100179), 1-10.
DOI Scopus38 WoS34 Europe PMC22
2022 Pandopulos, A. J., Simpson, B. S., White, J. M., Bade, R., & Gerber, C. (2022). Partitioning of phytocannabinoids between faeces and water - implications for wastewater-based epidemiology. Science of the Total Environment, 805(150269), 1-9.
DOI Scopus10 WoS9 Europe PMC6
2022 Othman, A. A., Simpson, B. S., Jaunay, E. L., White, J. M., Bade, R., & Gerber, C. (2022). A method for improved detection of 8-isoprostaglandin F2α/β and benzodiazepines in wastewater. Science of the Total Environment, 851(158061), 1-10.
DOI Scopus3 WoS1
2022 Bade, R., White, J. M., Ghetia, M., Adiraju, S., Adhikari, S., Bijlsma, L., . . . Gerber, C. (2022). A Taste for New Psychoactive Substances: Wastewater Analysis Study of 10 Countries. Environmental Science and Technology Letters, 9(1), 57-63.
DOI Scopus42 WoS34
2022 Simpson, B. S., Jaunay, E. L., Ghetia, M., Nguyen, L., Bade, R., White, J. M., & Gerber, C. (2022). Methcathinone in wastewater: drug of choice, or artefact?. Science of the Total Environment, 836, 1-5.
DOI Scopus15 WoS12 Europe PMC11
2021 Bade, R., Tscharke, B. J., O’Brien, J. W., Magsarjav, S., Humphries, M., Ghetia, M., . . . Gerber, C. (2021). Impact of COVID-19 Controls on the Use of Illicit Drugs and Alcohol in Australia. Environmental Science & Technology Letters, 8(9), 799-804.
DOI Scopus35 WoS31 Europe PMC25
2021 Vogel, A. P., Pearson-Dennett, V., Magee, M., Wilcox, R. A., Esterman, A., Thewlis, D., . . . Todd, G. (2021). Adults with a history of recreational cannabis use have altered speech production. Drug and Alcohol Dependence, 227(article no. 108963), 1-8.
DOI Scopus5 WoS3 Europe PMC6
2021 Bade, R., Simpson, B. S., Ghetia, M., Nguyen, L., White, J. M., & Gerber, C. (2021). Changes in alcohol consumption associated with social distancing and self‐isolation policies triggered by COVID‐19 in South Australia: a wastewater analysis study. Addiction, 116(6), 1600-1605.
DOI Scopus68 WoS61 Europe PMC52
2021 Bade, R., Ghetia, M., Chappell, A., White, J. M., & Gerber, C. (2021). Pholedrine is a marker of direct disposal of methamphetamine. Science of the Total Environment, 782, 1-5.
DOI Scopus7 WoS6 Europe PMC5
2021 Pandopulos, A. J., Bade, R., Tscharke, B. J., O'Brien, J. W., Simpson, B. S., White, J. M., & Gerber, C. (2021). Application of catecholamine metabolites as endogenous population biomarkers for wastewater-based epidemiology. Science of the Total Environment, 763(142992), 1-8.
DOI Scopus23 WoS18 Europe PMC13
2021 Bade, R., White, J. M., & Gerber, C. (2021). How the recreational stimulant market has changed: case study in Adelaide, Australia 2016-2019. Science of the Total Environment, 757(143728), 1-8.
DOI Scopus17 WoS14 Europe PMC9
2021 Bade, R., White, J. M., Chen, J., Baz Lomba, J. A., Been, F., Bijlsma, L., . . . Gerber, C. (2021). International snapshot of new psychoactive substance use: case study of eight countries over the 2019/2020 new year period. Water Research, 193(116891), 1-12.
DOI Scopus45 WoS41 Europe PMC25
2021 Pandopulos, A. J., Simpson, B. S., Bade, R., O'Brien, J. W., Yadav, M. K., White, J. M., & Gerber, C. (2021). A method and its application to determine the amount of cannabinoids in sewage sludge and biosolids. Environmental Science and Pollution Research, 28(42), 59652-59664.
DOI Scopus15 WoS12 Europe PMC11
2021 Vitry, A., Forte, G., & White, J. (2021). Access to controlled medicines in low-income countries: listening to stakeholders in the field. International Journal of Health Services, 51(3), 404-411.
DOI Scopus3 WoS3 Europe PMC3
2020 Pandopulos, A. J., Bade, R., O'Brien, J. W., Tscharke, B. J., Mueller, J. F., Thomas, K., . . . Gerber, C. (2020). Towards an efficient method for the extraction and analysis of cannabinoids in wastewater. Talanta, 217(121034), 1-10.
DOI Scopus58 WoS51 Europe PMC31
2020 Bade, R., White, J. M., Tscharke, B. J., Ghetia, M., Abdelaziz, A., & Gerber, C. (2020). Anabasine‐based measurement of cigarette consumption using wastewater analysis. Drug Testing and Analysis, 12(9), 1393-1398.
DOI Scopus14 WoS10 Europe PMC8
2020 Pandopulos, A. J., Gerber, C., Tscharke, B. J., O'Brien, J., White, J. M., & Bade, R. (2020). A sensitive analytical method for the measurement of neurotransmitter metabolites as potential population biomarkers in wastewater. Journal of Chromatography A, 1612(460623), 1-9.
DOI Scopus20 WoS20 Europe PMC15
2020 Bade, R., Ghetia, M., White, J. M., & Gerber, C. (2020). Determination of prescribed and designer benzodiazepines and metabolites in influent wastewater. Analytical Methods, 12(28), 3637-3644.
DOI Scopus38 WoS34 Europe PMC24
2020 Gerber, C., Bade, R., & White, J. (2020). Amphetamine dependence in Australia. The Lancet, 396(10256), 957.
DOI WoS1 Europe PMC1
2020 Bade, R., White, J. M., Nguyen, L., Pandopulos, A. J., & Gerber, C. (2020). What is the drug of choice of young festivalgoers?. Drug and Alcohol Dependence, 216(108315), 1-5.
DOI Scopus16 WoS13 Europe PMC12
2020 Bade, R., Abdelaziz, A., Nguyen, L., Pandopulos, A. J., White, J. M., & Gerber, C. (2020). Determination of 21 synthetic cathinones, phenethylamines, amphetamines and opioids in influent wastewater using liquid chromatography coupled to tandem mass spectrometry. Talanta, 208(120479), 1-8.
DOI Scopus80 WoS69 Europe PMC42
2020 Somogyi, A. A., Athanasos, P., White, J., Bochner, F., & Ling, W. (2020). Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose.. Pain medicine (Malden, Mass.), 21(9), 2007-2008.
DOI Scopus1 WoS1
2020 Bade, R., White, J. M., Nguyen, L., Tscharke, B. J., Mueller, J. F., O'Brien, J. W., . . . Gerber, C. (2020). Determining changes in new psychoactive substance use in Australia by wastewater analysis. Science of the Total Environment, 731(article no. 139209), 1-9.
DOI Scopus46 WoS39 Europe PMC24
2020 Bade, R., Abbate, V., Abdelaziz, A., Nguyen, L., Trobbiani, S., Stockham, P., . . . Gerber, C. (2020). The complexities associated with new psychoactive substances in influent wastewater: the case of 4‐ethylmethcathinone. Drug Testing and Analysis, 12(10), 1494-1500.
DOI Scopus5 WoS4 Europe PMC4
2019 Pajcin, M., White, J. M., Banks, S., Dorrian, J., Paech, G. M., Grant, C. L., . . . Della Vedova, C. B. (2019). Effects of strategic early-morning caffeine gum administration on association between salivary alpha-amylase and neurobehavioural performance during 50 h of sleep deprivation. Accident Analysis and Prevention, 126, 160-172.
DOI Scopus4 WoS3 Europe PMC3
2019 Athanasos, P., Ling, W., Bochner, F., White, J. M., & Somogyi, A. A. (2019). Buprenorphine maintenance subjects are hyperalgesic and have no antinociceptive response to a very high morphine dose. Pain Medicine, 20(1), 119-128.
DOI Scopus28 WoS28 Europe PMC22
2019 Pearson-Dennett, V., Faulkner, P. L., Collie, B., Wilcox, R. A., Vogel, A. P., Thewlis, D., . . . Todd, G. (2019). Use of illicit amphetamines is associated with long-lasting changes in hand circuitry and control. Clinical Neurophysiology, 130(5), 655-665.
DOI Scopus4 WoS4 Europe PMC3
2019 Bade, R., Ghetia, M., Nguyen, L., Tscharke, B. J., White, J. M., & Gerber, C. (2019). Simultaneous determination of 24 opioids, stimulants and new psychoactive substances in wastewater. MethodsX, 6, 953-960.
DOI Scopus42 WoS37 Europe PMC31
2019 Todd, G., Burns, L., Pearson-Dennett, V., Esterman, A., Faulkner, P. L., Wilcox, R. A., . . . White, J. M. (2019). Prevalence of self-reported movement dysfunction among young adults with a history of ecstasy and methamphetamine use. Drug and Alcohol Dependence, 205(107595), 107595-1-107595-9.
DOI Scopus5 WoS4 Europe PMC3
2019 McDonough, M., Johnson, J. L., White, J. M., & Buisman-Pijlman, F. T. A. (2019). Measuring opioid dependence in chronic pain patients: A comparison between addiction clinic and pain clinic patient populations.. Journal of opioid management, 15(4), 285-293.
DOI Scopus4 Europe PMC3
2019 Peacock, A., Bruno, R., Gisev, N., Degenhardt, L., Hall, W., Sedefov, R., . . . Griffiths, P. (2019). New psychoactive substances: challenges for drug surveillance, control, and public health responses. The lancet, 394(10209), 1668-1684.
DOI Scopus267 WoS223 Europe PMC164
2019 Pajcin, M., Banks, S., Dorrian, J., Gupta, C. C., Coates, A. M., Grant, C. L., . . . Della Vedova, C. B. (2019). Salivary levels of alpha-amylase are associated with neurobehavioral alertness during extended wakefulness, but not simulated night-shift work. Physiology and behavior, 204, 1-9.
DOI Scopus7 WoS5 Europe PMC6
2019 Bade, R., Stockham, P., Painter, B., Celma, A., Bijlsma, L., Hernandez, F., . . . Gerber, C. (2019). Investigating the appearance of new psychoactive substances in South Australia using wastewater and forensic data. Drug testing and analytics, 11(2), 250-256.
DOI Scopus39 WoS32 Europe PMC24
2019 Bade, R., Tscharke, B. J., White, J. M., Grant, S., Mueller, J. F., O'Brien, J., . . . Gerber, C. (2019). LC-HRMS suspect screening to show spatial patterns of new psychoactive substances use in Australia. Science of the total environment, 650(Pt 2), 2181-2187.
DOI Scopus69 WoS56 Europe PMC43
2018 Bade, R., White, J., & Gerber, C. (2018). Qualitative and quantitative temporal analysis of licit and illicit drugs in wastewater in Australia using liquid chromatography coupled to mass spectrometry. Analytical and bioanalytical chemistry, 410(2), 529-542.
DOI Scopus47 WoS38 Europe PMC20
2018 Hotham, E., Haberfield, M., Hillier, S., White, J., & Todd, G. (2018). Upper limb function in children with attention-deficit/hyperactivity disorder (ADHD). Journal of Neural Transmission, 125(4), 713-726.
DOI Scopus26 WoS25 Europe PMC16
2018 Bade, R., Tscharke, B. J., Longo, M., Cooke, R., White, J. M., & Gerber, C. (2018). Investigating the correlation between wastewater analysis and roadside drug testing in South Australia. Drug and alcohol dependence, 187, 123-126.
DOI Scopus17 WoS15 Europe PMC9
2018 Lai, F. Y., Gartner, C., Hall, W., Carter, S., O'Brien, J., Tscharke, B. J., . . . Mueller, J. F. (2018). Measuring spatial and temporal trends of nicotine and alcohol consumption in Australia using wastewater-based epidemiology. Addiction, 113(6), 1127-1136.
DOI Scopus71 WoS66 Europe PMC54
2018 Stallman, H., Kohler, M., & White, J. (2018). Medication induced sleepwalking: A systematic review. Sleep Medicine Reviews, 37, 105-113.
DOI Scopus86 WoS64 Europe PMC55
2018 Ezard, N., Dunlop, A., Hall, M., Ali, R., McKetin, R., Bruno, R., . . . Lintzeris, N. (2018). LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. BMJ Open, 8(7), e020723.
DOI Scopus17 WoS14 Europe PMC14
2017 Pajcin, M., Banks, S., White, J. M., Dorrian, J., Paech, G. M., Grant, C., . . . Della Vedova, C. B. (2017). Decreased salivary alpha-amylase levels are associated with performance deficits during sleep loss. Psychoneuroendocrinology, 78, 131-141.
DOI Scopus26 WoS26 Europe PMC21
2017 Newcombe, D., Somogyi, A., Bochner, F., & White, J. (2017). Impaired psychomotor function and plasma methadone and levo-alpha-acetylmethadol (LAAM) concentrations in opioid-substitution patients. Experimental and Clinical Psychopharmacology, 25(3), 223-233.
DOI Scopus3 WoS3 Europe PMC1
2017 Gowing, L., Ali, R., & White, J. (2017). Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database of Systematic Reviews, 2017(5), 55 pages.
DOI Scopus38 WoS17 Europe PMC14
2017 Pearson-Dennett, V., Todd, G., Wilcox, R., Vogel, A., White, J., & Thewlis, D. (2017). History of cannabis use is associated with altered gait. Drug and Alcohol Dependence, 178, 215-222.
DOI Scopus14 WoS12 Europe PMC9
2017 Gowing, L., Ali, R., White, J., & Mbewe, D. (2017). Buprenorphine for managing opioid withdrawal. Cochrane Database of Systematic Reviews, 2017(2), 1-95.
DOI Scopus130 WoS114 Europe PMC70
2017 Crowley, P., White, J. M., Tscharke, B. J., & Gerber, C. (2017). Wastewater analysis shows a large decrease in oxycodone use in Adelaide. Medical journal of Australia, 207(2), 88-89.
DOI Scopus2 WoS2 Europe PMC1
2016 Todd, G., Pearson Dennett, V., Flavel, S., Haberfield, M., Edwards, H., & White, J. M. (2016). History of illicit stimulant use is not associated with long-lasting changes in learning of fine motor skills in humans. Neural Plasticity, 2016(9485079), 1-11.
DOI Scopus3 WoS3 Europe PMC2
2016 Tscharke, B. J., Chen, C., Gerber, J. P., & White, J. (2016). Temporal trends in drug use in Adelaide, South Australia by wastewater analysis. Science of the total environment, 565, 384-391.
DOI Scopus128 WoS113 Europe PMC72
2016 Tscharke, B. J., White, J. M., & Gerber, J. P. (2016). Estimates of tobacco use by wastewater analysis of anabasine and anatabine. Drug testing and analysis, 8(7), 702-707.
DOI Scopus38 WoS32 Europe PMC25
2016 Hotham, E. D., Ali, R. L., White, J. M., & Robinson, J. S. (2016). Ethical considerations when researching with pregnant substance users and implications for practice. Addictive Behaviors, 60, 242-243.
DOI Scopus3 WoS2 Europe PMC1
2016 Hotham, E., Ali, R., & White, J. (2016). Analysis of qualitative data from the investigation study in pregnancy of the ASSIST Version 3.0 (the Alcohol, Smoking and Substance Involvement Screening Test). Midwifery, 34, 183-197.
DOI Scopus11 WoS9 Europe PMC6
2016 Todd, G., Pearson-Dennett, V., Wilcox, R., Chau, M., Thoirs, K., Thewlis, D., . . . White, J. (2016). Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism. Parkinsonism and Related Disorders, 25, 27-32.
DOI Scopus36 WoS32 Europe PMC27
2016 Gowing, L., Farrell, M., Ali, R., & White, J. (2016). Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, 2016(5), 88 pages.
DOI Scopus101 WoS120 Europe PMC51
2015 Kershaw, S., Della Vedova, C., Majumder, I., Ward, M., Farquharson, A., Williamson, P., & White, J. (2015). Acute opioid administration induces hypothalamic-pituitary-adrenal activation and is mediated by genetic variation in interleukin (Il)1B. Pharmacology, Biochemistry and Behavior, 138, 9-13.
DOI Scopus6 WoS6 Europe PMC6
2015 Tscharke, B. J., Chen, C., Gerber, J. P., & White, J. M. (2015). Trends in stimulant use in Australia: a comparison of wastewater analysis and population surveys. Science of the total environment, 536, 331-337.
DOI Scopus38 WoS39 Europe PMC26
2015 Kershaw, S. G., Dry, M., Della Vedova, C., Majumder, I., Ward, M., Williamson, P., & White, J. (2015). Inspection time as a general measure of cognitive impairment following acute opioid exposure. Drug and Alcohol Dependence, 156, e108.
DOI
2014 Gowing, L., Farrell, M., Ali, R., & White, J. (2014). Alpha2-adrenergic agonists for the management of opioid withdrawal (review). The Cochrane database of systematic reviews, 3(3), CD002024-1-CD002024-87.
DOI Scopus87 WoS29 Europe PMC30
2014 Pearson-Dennett, V., Flavel, S., Wilcox, R., Thewlis, D., Vogel, A., White, J., & Todd, G. (2014). Hand function is altered in individuals with a history of illicit stimulant use. PLoS One, 9(12), e115771-1-e115771-16.
DOI Scopus8 WoS8 Europe PMC5
2014 Chen, C., Kostakis, C., Gerber, J., Tscharke, B., Irvine, R., & White, J. (2014). Towards finding a population biomarker for wastewater epidemiology studies. Science of the Total Environment, 487(1), 621-628.
DOI Scopus132 WoS117 Europe PMC88
2013 Chen, C., Kostakis, C., Irvine, R., & White, J. (2013). Increases in use of novel synthetic stimulant are not directly linked to decreased use of 3,4-methylenedioxy-N-methylamphetamine (MDMA). Forensic Science International, 231(1), 278-283.
DOI Scopus53 WoS44 Europe PMC36
2013 Hotham, E., Ali, R., White, J., Sullivan, T., & Robinson, J. (2013). Investigation of the Alcohol, Smoking, and Substance Involvement Screening Test (the ASSIST) Version 3.0 in pregnancy. Addictive Disorders & Their Treatment, 12(3), 123-135.
DOI Scopus8 WoS6
2013 Chen, C., Kostakis, C., Irvine, R., Felgate, P., & White, J. (2013). Evaluation of pre-analysis loss of dependent drugs in wastewater: stability and binding assessments. Drug Testing and Analysis, 5(8), 716-721.
DOI Scopus58 WoS52 Europe PMC30
2013 White, J. (2013). Blocking endogenous opioids during development: do we understand the consequences?. Addiction, 108(2), 251-252.
DOI Scopus3 WoS3 Europe PMC3
2013 Todd, G., Noyes, C., Flavel, S., Della Vedova, C. B., Spyropoulos, P., Chatterton, B., . . . White, J. M. (2013). Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS one, 8(2), article no. e56438.
DOI Scopus46 WoS41 Europe PMC37
2013 Flavel, S. C., White, J. M., & Todd, G. (2013). Abnormal maximal finger tapping in abstinent cannabis users. Human psychopharmacology: clinical and experimental, 28(6), 612-614.
DOI Scopus8 WoS7 Europe PMC5
2012 Flavel, S. C., Koch, J. D., White, J. M., & Todd, G. (2012). Illicit stimulant use in humans is associated with a long-term increase in tremor. PLoS one, 7(12, article no. e52025), 1-9.
DOI Scopus25 WoS19 Europe PMC15
2012 Gordon, A. L., Lopatko, O. V., Stacey, H., Pearson, V., Woods, A., Fisk, A., & White, J. M. (2012). Patterns of symptom reporting during pregnancy comparing opioid maintained and control women. Journal of addiction medicine, 6(4), 258-264.
DOI Scopus6 WoS4 Europe PMC4
2012 Flavel, S. C., White, J. M., & Todd, G. (2012). Motor cortex and corticospinal excitability in humans with a history of illicit stimulant use. Journal of applied physiology, 113(9), 1486-1494.
DOI Scopus21 WoS19 Europe PMC16
2012 Krishnan, S., Salter, A., Sullivan, T., Gentgall, M., White, J., & Rolan, P. (2012). Comparison of pain models to detect opioid-induced hyperalgesia. Journal of Pain Research, 2012(5), 99-106.
DOI Scopus28 Europe PMC24
2012 Dry, M., Burns, N., Nettelbeck, T., Farquharson, A., & White, J. (2012). Dose-related effects of alcohol on cognitive functioning. PLoS One, 7(11), 1-8.
DOI Scopus117 WoS108 Europe PMC76
2012 Coller, J., Michalakas, J., James, H., Farquharson, A., Colvill, J., White, J., & Somogyi, A. (2012). Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. British Journal of Clinical Pharmacology, 74(5), 835-841.
DOI Scopus22 WoS18 Europe PMC15
2012 Hotham, E., White, J., Ali, R., & Robinson, J. (2012). Screening for use of alcohol, tobacco and cannabis in pregnancy using self-report tools. Journal of Developmental Origins of Health and Disease, 3(4), 216-223.
DOI Scopus1
2012 Gordon, A., Lopatko, O., Haslam, R., Stacey, H., Pearson, V., Woods, A., . . . White, J. (2012). Ineffective morphine treatment regimen for the control of Neonatal Abstinence Syndrome in buprenorphine- and methadone-exposed infants. Journal of Developmental Origins of Health and Disease, 3(4), 262-270.
DOI Scopus11 WoS11 Europe PMC9
2012 Majumder, I., White, J., & Irvine, R. (2012). Antidepressant-like effects of ecstasy in subjects with a predisposition to depression. Addictive Behaviors, 37(10), 1189-1192.
DOI Scopus18 WoS16 Europe PMC13
2012 Barratt, D., Coller, J., Hallinan, R., Byrne, A., White, J., Foster, D., & Somogyi, A. (2012). ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 5(1), 53-62.
DOI Scopus48 WoS43 Europe PMC38
2012 Gelston, E., Coller, J., Lopatko, O., James, H., Schmidt, H., White, J., & Somogyi, A. (2012). Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. British Journal of Clinical Pharmacology, 73(5), 786-794.
DOI Scopus28 WoS25 Europe PMC20
2012 Savvas, S., Somogyi, A., & White, J. (2012). The effect of methadone on emotional reactivity. Addiction, 107(2), 388-392.
DOI Scopus21 WoS18 Europe PMC11
2011 Coller, J., Cahill, S., Edmonds, C., Farquharson, A., Longo, M., Minniti, R., . . . White, J. (2011). OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 21(12), 902-905.
DOI Scopus40 WoS34 Europe PMC32
2011 Majumder, I., White, J., & Irvine, R. (2011). Antidepressant-like effects of 3,4-methylenedioxymethamphetamine in an animal model of depression. Behavioural Pharmacology, 22(8), 758-765.
DOI Scopus12 WoS13 Europe PMC13
2011 Chen, C., Kostakis, C., Harpas, P., Felgate, P., Irvine, R., & White, J. (2011). Marked decline in 3,4-methylenedioxymethamphetamine (MDMA) based on wastewater analysis. Journal of Studies on Alcohol and Drugs, 72(5), 737-740.
DOI Scopus18 WoS16 Europe PMC14
2011 Hay, J., La Vincente, S., Somogyi, A., Chapleo, C., & White, J. (2011). Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. European Journal of Pain, 15(3), 293-298.
DOI Scopus16 WoS13 Europe PMC12
2011 Irvine, R., Kostakis, C., Felgate, P., Jaehne, E., Chen, C., & White, J. (2011). Population drug use in Australia: A wastewater analysis. Forensic Science International, 210(1-3), 69-73.
DOI Scopus134 WoS126 Europe PMC93
2011 Morefield, K., Keane, M., Felgate, P., White, J., & Irvine, R. (2011). Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Addiction, 106(7), 1293-1300.
DOI Scopus55 WoS52 Europe PMC46
2010 Gordon, A., Lopatko, O., Somogyi, A., Foster, D., & White, J. (2010). (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. British Journal of Clinical Pharmacology, 70(6), 895-902.
DOI Scopus31 WoS29 Europe PMC24
2010 Smout, M., Longo, M., Harrison, S., Minniti, R., Cahill, S., Wickes, W., & White, J. (2010). The psychostimulant check-up: A pilot study of a brief intervention to reduce illicit stimulant use. Drug and Alcohol Review, 29(2), 169-176.
DOI Scopus5 WoS4 Europe PMC3
2010 Whitham, J., Spurrier, N., Sawyer, M., Baghurst, P., Taplin, J., White, J., & Gordon, A. (2010). The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicology and Teratology, 32(2), 280-288.
DOI Scopus50 WoS44 Europe PMC37
2010 Hay, J., Kaboutari, J., White, J., Salem, A., & Irvine, R. (2010). Model of methadone-induced hyperalgesia in rats and effect of memantine. European Journal of Pharmacology, 626(2-3), 229-233.
DOI Scopus15 WoS13 Europe PMC10
2010 Gowing, L., Ali, R., & White, J. (2010). Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. The Cochrane Database of Systematic Reviews, (1), CD002022.
DOI Scopus25 WoS4
2010 Smout, M., Longo, M., Harrison, S., Minniti, R., Wickes, W., & White, J. (2010). Psychosocial treatment for methamphetamine use disorders: A preliminary randomized controlled trial of cognitive behavior therapy and acceptance and commitment therapy. Substance Abuse, 31(2), 98-107.
DOI Scopus105 WoS86 Europe PMC59
2009 White, J. (2009). Drug Addiction: From Basic Research to Therapy. DRUG AND ALCOHOL REVIEW, 28(4), 1 page.
2009 Liu, L., Hutchinson, M., White, J., Somogyi, A., & Coller, J. (2009). Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 19(11), 869-876.
DOI Scopus42 WoS38 Europe PMC38
2009 Gowing, L., Ali, R., & White, J. (2009). Opioid antagonists with minimal sedation for opioid withdrawal. The Cochrane Database of Systematic Reviews, 2009(4), 1-47.
DOI Scopus30 WoS20 Europe PMC13
2009 Gowing, L., Ali, R., & White, J. (2009). Buprenorphine for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews, 2009(3), 1-76.
DOI Scopus188 WoS72 Europe PMC54
2009 Gowing, L., Farrell, M., Ali, R., & White, J. (2009). Alpha₂-adrenergic agonists for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews, Online(2), 1-87.
DOI Scopus109 WoS46 Europe PMC20
2009 White, J., Bell, J., Saunders, J., Williamson, P., Makowska, M., Farquharson, A., & Beebe, K. (2009). Open-label dose-finding trial of buprenorphine implants (Probuphine)® for treatment of heroin dependence. Drug and Alcohol Dependence, 103(1-2), 37-43.
DOI Scopus67 WoS55 Europe PMC38
2009 Hay, J., White, J., Bochner, F., Somogyi, A., Semple, T., & Rousefell, B. (2009). Hyperalgesia in Opioid-Managed Chronic Pain and Opioid-Dependent Patients. The Journal of Pain, 10(3), 316-322.
DOI Scopus140 WoS115 Europe PMC94
2009 Longo, M., Wickes, W., Smout, M., Harrison, S., Cahill, S., & White, J. (2009). Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction, 105(1), 146-154.
DOI Scopus107 WoS87 Europe PMC73
2008 Elkashef, A., Vocci, F., Hanson, G., White, J., Wickes, W., & Tiihonen, J. (2008). Pharmacotherapy of methamphetamine addiction: an update. Substance Abuse, 29(3), 31-49.
DOI Scopus111 WoS98 Europe PMC79
2008 Gibson, A., Degenhardt, L., Mattick, R., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. Addiction, 103(3), 462-468.
DOI Scopus166 WoS158 Europe PMC129
2008 Somogyi, A., Larsen, M., Abadi, R., Jittiwutikarn, J., Ali, R., & White, J. (2008). Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology, 66(5), 640-647.
DOI Scopus19 WoS20 Europe PMC15
2008 McGregor, C., Srisurapanont, M., Mitchell, A., Wickes, W., & White, J. (2008). Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: A comparison of mirtazapine and modafinil with treatment as usual. Journal of Substance Abuse Treatment, 35(3), 334-342.
DOI Scopus70 WoS60 Europe PMC53
2008 Hay, J., White, J., Bochner, F., & Somogyi, A. (2008). Antinociceptive effects of high dose remifentanil in male methadone-maintained patients. European Journal of Pain, 12(7), 926-933.
DOI Scopus19 WoS17 Europe PMC11
2008 Hotham, E., Ali, R., White, J., & Robinson, J. (2008). Pregnancy-related changes in tobacco, alcohol and cannabis use reported by antenatal patients at two public hospitals in South Australia. Australian & New Zealand Journal of Obstetrics & Gynaecology, 48(3), 248-254.
DOI Scopus41 WoS36 Europe PMC31
2008 McGregor, C., Srisurapanont, M., Mitchell, A., Longo, M., Cahill, S., & White, J. (2008). Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. Journal of Substance Abuse Treatment, 34(4), 443-449.
DOI Scopus38 WoS30 Europe PMC28
2008 Yelland, L., Burns, J., Sims, N., Salter, A., & White, J. (2008). Inter- and intra-subject variability in ethanol pharmacokinetic parameters: effects of testing interval and dose.. Forensic Science International, 175(1), 65-72.
DOI Scopus12 WoS9 Europe PMC7
2008 La Vincente, S., White, J., Somogyi, A., Bochner, F., & Chapleo, C. (2008). Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clinical Pharmacology & Therapeutics, 83(1), 144-152.
DOI Scopus29 WoS19 Europe PMC15
2007 White, J., & Lopatko, O. (2007). Opioid maintenance: a comparative review of pharmacological strategies. Expert Opinion on Pharmacotherapy, 8(1), 1-11.
DOI Scopus27 WoS31 Europe PMC22
2006 O'Brien, S., Mattick, R., White, J., Breen, C., Kimber, J., Ritter, A., & Lintzeris, N. (2006). Maintenance pharmacotherapy for opioid dependence and SF-36 Health status: a comparison with general population norms and other chronic disorders. Addictive Disorders & Their Treatment, 5(4), 155-164.
DOI Scopus17 WoS15
2006 Mitchell, T., White, J., Somogyi, A., & Bochner, F. (2006). Switching between methadone and morphine for maintenance treatment of opioid dependence: Impact on pain sensitivity and mood status. American Journal on Addictions, 15(4), 311-315.
DOI Scopus16 WoS13 Europe PMC12
2006 Mitchell, T., Dyer, K., Newcombe, D., Somogyi, A., & White, J. (2006). Fluctuations in (R,S)-methadone pharmacokinetics and response among long-term methadone maintenance patients. Addiction Biology, 11(2), 170-174.
DOI Scopus5 WoS3 Europe PMC5
2006 Gowing, L., Ali, R., & White, J. (2006). Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal (review). The Cochrane Database of Systematic Reviews, Online(Issue 2. Art. No. CD002022), 1-26.
DOI Scopus43 WoS44 Europe PMC16
2006 Irvine, R., Keane, M., Felgate, P., McCann, U., Callaghan, P., & White, J. (2006). Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology, 31(2), 424-430.
DOI Scopus48 WoS43 Europe PMC42
2006 Gowing, L., Ali, R., & White, J. (2006). Opioid antagonists with minimal sedation for opioid withdrawal (review). The Cochrane Database of Systematic Reviews, Online(1AR CD002021DI ARTN CD002021), 2021.
DOI Scopus14 WoS4 Europe PMC8
2006 Athanasos, P., Smith, C., White, J., Somogyi, A., Bochner, F., & Ling, W. (2006). Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain, 120(3), 267-275.
DOI Scopus90 WoS76 Europe PMC70
2006 Shanahan, M., Doran, C., Digiusto, E., Bell, J., Lintzeris, N., White, J., . . . Gilmour, S. (2006). A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addictive Behaviors, 31(3), 371-387.
DOI Scopus21 WoS17 Europe PMC13
2006 Digiusto, E., Shakeshaft, A., Ritter, A., Mattick, R. P., White, J. M., Lintzeris, N., . . . Saunders, J. (2006). Effects of pharmacotherapies for opioid dependence on participants' criminal behaviour and expenditure on illicit drugs: An Australian national evaluation (NEPOD). Australian and New Zealand Journal of Criminology, 39(2), 171-189.
DOI Scopus11 WoS8
2005 Digiusto, E., Lintzeris, N., Breen, C., Kimber, J., Mattick, R., Bell, J., . . . Saunders, J. (2005). Short-term outcomes of five heroin detoxification methods in the Australian NEPOD project. Addictive Behaviors, 30(3), 443-456.
DOI Scopus18 WoS17 Europe PMC14
2005 Hanna, J., Foster, D., Salter, A., Somogyi, A., White, J., & Bochner, F. (2005). Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. British Journal of Clinical Pharmacology, 60(4), 404-413.
DOI Scopus23 WoS22 Europe PMC16
2005 McGregor, C., Srisurapanont, M., Jittiwutikarn, J., Laobhripatr, S., Wongtan, T., & White, J. (2005). The nature, time course and severity of methamphetamine withdrawal. Addiction, 100(9), 1320-1329.
DOI Scopus330 WoS278 Europe PMC238
2004 White, J. (2004). Pleasure into pain: the consequences of long-term opioid use. Addictive Behaviors, 29(7), 1311-1324.
DOI Scopus113 WoS91 Europe PMC74
2004 Athanasos, P., Morrish, G., Somogyi, A., Bochner, F., & White, J. (2004). Changes in methadone concentration, opiod effects, and opioid withdrawal during induction onto maintenance treatment. Addictive Disorders & Their Treatment, 3(3), 122-128.
DOI
2004 Newcombe, D., Bochner, F., White, J., & Somogyi, A. (2004). Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. Drug and Alcohol Dependence, 76(1), 63-72.
DOI Scopus24 WoS20 Europe PMC13
2004 Mitchell, T., Dyer, K., Newcombe, D., Salter, A., Somogyi, A., Bochner, F., & White, J. (2004). Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. British Journal of Clinical Pharmacology, 58(6), 609-617.
DOI Scopus47 WoS40 Europe PMC31
2004 Jittiwutikarn, J., Ali, R., White, J., Bochner, F., Somogyi, A., & Foster, D. (2004). Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. British Journal of Clinical Pharmacology, 58(5), 536-541.
DOI Scopus20 WoS17 Europe PMC11
2004 Mitchell, T., White, J., Somogyi, A., & Bochner, F. (2004). Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction, 99(8), 940-945.
DOI Scopus65 WoS60 Europe PMC46
2004 Foster, D., Somogyi, A., White, J., & Bochner, F. (2004). Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 57(6), 742-755.
DOI Scopus72 WoS61 Europe PMC51
2004 Bexis, S., Phillis, B., Ong, J., White, J., & Irvine, R. (2004). Baclofen prevents MDMA-induced rise in core body temperature in rats. Drug and Alcohol Dependence, 74(1), 89-96.
DOI Scopus19 WoS17 Europe PMC13
2004 Lewanowitsch, T., White, J., & Irvine, R. (2004). Use of radiotelemetry to evaluate respiratory depression produced by chronic methadone administration. European Journal of Pharmacology, 484(2-3), 303-310.
DOI Scopus9 WoS9 Europe PMC7
2004 Gowing, L., Ali, R., & White, J. (2004). Buprenorphine for the management of opioid withdrawal.. Cochrane Database of Systematic Reviews Online, (4), CD002025.
DOI Scopus34 Europe PMC15
2003 Gowing, L., Farrell, M., Ali, R., & White, J. (2003). Alpha2 adrenergic agonists for the management of opioid withdrawal.. Cochrane database of systematic reviews (Online), (2), CD002024.
DOI Scopus6 Europe PMC12
2003 Mitchell, T., White, J., Somogyi, A., & Bochner, F. (2003). Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug and Alcohol Dependence, 72(1), 85-94.
DOI Scopus50 WoS45 Europe PMC36
2003 Ali, R., Thomas, P., White, J., McGregor, C., Danz, C., Gowing, L., . . . Athanasos, P. (2003). Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. Drug and Alcohol Review, 22(4), 425-431.
DOI Scopus11 WoS11 Europe PMC8
2003 Mattick, R., Ali, R., White, J., O'Brien, S., Wolk, S., & Danz, C. (2003). Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction, 98(4), 441-452.
DOI Scopus249 WoS218 Europe PMC179
2003 Lopatko, O., White, J., Huber, A., & Ling, W. (2003). Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. Drug and Alcohol Dependence, 69(3), 317-322.
DOI Scopus23 WoS17 Europe PMC16
2003 McGregor, C., Machin, A., & White, J. (2003). In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. Drug and Alcohol Review, 22(2), 175-180.
DOI Scopus37 WoS33 Europe PMC28
2003 Doran, C., Shanahan, M., Mattick, R., Ali, R., White, J., & Bell, J. (2003). Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug and Alcohol Dependence, 71(3), 295-302.
DOI Scopus98 WoS82 Europe PMC72
2002 Doverty, M., White, J., Somogyi, A., Bochner, F., Ali, R., & Ling, W. (2002). Reply to Dr. Clark's comment on Doverty et al., hyperalgesic responses in methadone maintenance patients (Pain 2001;90 : 91-96). Pain, 99(3), 609-610.
DOI WoS1
2002 Gowing, L., Ali, R., & White, J. (2002). Which substitution pharmacotherapy is most effective in treating opioid dependence?. Medical Journal of Australia, 176(10), 493-494.
DOI
2002 Kaminskas, L., Irvine, R., Callaghan, P., White, J., & Kirkbride, P. (2002). The contribution of the metabolite p-hydroxyamphetamine to the central actions of p-methoxyamphetamine. Psychopharmacology, 160(2), 155-160.
DOI Scopus17 WoS12 Europe PMC8
2002 White, J., Danz, C., Kneebone, J., La Vincente, S., Newcombe, D., & Ali, R. (2002). Relationship between LAAM-methadone preference and treatment outcomes. Drug and Alcohol Dependence, 66(3), 295-301.
DOI Scopus20 WoS18 Europe PMC16
2002 Porter, S., Somogyi, A., & White, J. (2002). In vivo and in vitro potency studies of 6b-naltrexol, the major human metabolite of naltrexone. Addiction Biology, 7(2), 219-225.
DOI Scopus44 WoS39 Europe PMC34
2002 Gowing, L., Farrell, M., Ali, R., & White, J. (2002). a₂-Adrenergic agonists in opioid withdrawal. Addiction, 97(1), 49-58.
DOI Scopus63 WoS49 Europe PMC49
2002 McGregor, C., Ali, R., White, J., Thomas, P., & Gowing, L. (2002). A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug and Alcohol Dependence, 68(1), 5-14.
DOI Scopus35 WoS34 Europe PMC26
2002 Gowing, L., Ali, R., & White, J. (2002). Buprenorphine for the management of opioid withdrawal.. Cochrane Database of Systematic Reviews Online, (2), CD002025.
DOI Scopus31 Europe PMC17
2002 Gowing, L., Ali, R., & White, J. (2002). Opioid antagonists with minimal sedation for opioid withdrawal.. Cochrane database of systematic reviews (Online : Update Software), (2), CD002021.
DOI Scopus15 Europe PMC5
2002 Gowing, L., Ali, R., & White, J. (2002). Buprenorphine for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews, (2), CD002025-1-CD002025-22.
DOI Scopus21 Europe PMC6
2001 Gowing, L., Farrell, M., Ali, R., & White, J. (2001). Alpha2 adrenergic agonists for the management of opioid withdrawal.. Cochrane Database of Systematic Reviews Online, (1), CD002024.
DOI Scopus20 Europe PMC22
2001 Gowing, L., Ali, R., & White, J. (2001). Opioid antagonists under sedation or anaesthesia for opioid withdrawal.. Cochrane Database of Systematic Reviews Online, (1), CD002022.
DOI Scopus12 Europe PMC1
2001 Gowing, L., Ali, R., & White, J. (2001). Buprenorphine for the management of opioid withdrawal. Praxis, 90(44), 1934.
2001 Bexis, S., Ong, J., & White, J. (2001). Attenuation of morphine withdrawal signs by the GABAB receptor agonist baclofen. Life Sciences, 70(4), 395-401.
DOI Scopus34 WoS35 Europe PMC28
2001 Phillis, B., Ong, J., White, J., & Bonnielle, C. (2001). Modification of d-amphetamine-induced responses by baclofen in rats. Psychopharmacology, 153(3), 277-284.
DOI Scopus24 WoS20 Europe PMC22
2001 Doverty, M., Somogyi, A., White, J., Bochner, F., Beare, C., Menelaou, A., & Ling, W. (2001). Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain, 93(2), 155-163.
DOI Scopus153 WoS127 Europe PMC104
2001 Doverty, M., White, J., Somogyi, A., Bochner, F., Ali, R., & Ling, W. (2001). Hyperalgesic responses in methadone maintenance patients. Pain, 90(01-Feb), 91-96.
DOI Scopus276 WoS223 Europe PMC203
2001 Dyer, K., White, J., Foster, D., Bochner, F., Menelaou, A., & Somogyi, A. (2001). The relationship between mood state and plasma methadone concentration in maintenance patients. Journal of Clinical Psychopharmacology, 21(1), 78-84.
DOI Scopus65 WoS55 Europe PMC44
2001 Chew, M., White, J., Somogyi, A., Bochner, F., & Irvine, R. (2001). Precipitated withdrawal following codeine administration is dependent on CYP genotype. European Journal of Pharmacology, 425(3), 159-164.
DOI Scopus8 WoS7 Europe PMC6
2000 Gowing, L., Ali, R., & White, J. (2000). Opioid antagonists and adrenergic agonists for the management of opioid withdrawal. Praxis, 89(44), 1810-1811.
2000 Gowing, L., Ali, R., & White, J. (2000). Opioid antagonists and adrenergic agonists for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews, (2), 1-2.
DOI Scopus15 Europe PMC5
2000 Longo, M., Hunter, C., Lokan, R., White, J., & White, M. (2000). The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability. Part II: The relationship between drug prevalence and drug concentration, and driver culpability. Accident Analysis and Prevention, 32(5), 623-632.
DOI Scopus167 WoS137 Europe PMC102
2000 Longo, M., Hunter, C., Lokan, R., White, J., & White, M. (2000). The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability. Part I: the prevalence of drug use in drivers, and characteristics of the drug-positive group. Accident Analysis and Prevention, 32(5), 613-622.
DOI Scopus92 WoS73 Europe PMC52
2000 Gowing, L., Ali, R., & White, J. (2000). The management of opioid withdrawal. Drug and Alcohol Review, 19(3), 309-318.
DOI Scopus19 WoS16
2000 Gowing, L., Ali, R., & White, J. (2000). Systematic review processes and the management of opioid withdrawal. Australian and New Zealand Journal of Public Health, 24(4), 427-431.
DOI Scopus5 WoS3 Europe PMC4
2000 Daws, L., Irvine, R., Callaghan, P., Toop, N., White, J., & Bochner, F. (2000). Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Progress in Neuro-psychopharmacology & Biological Psychiatry, 24(6), 955-977.
DOI Scopus50 WoS47 Europe PMC33
2000 Porter, S., Somogyi, A., & White, J. (2000). Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol. British Journal of Clinical Pharmacology, 50(5), 465-471.
DOI Scopus58 WoS54 Europe PMC42
2000 Foster, D., Somogyi, A., Dyer, K., White, J., & Bochner, F. (2000). Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 50(5), 427-440.
DOI Scopus125 WoS106 Europe PMC86
2000 Gaughwin, M., Dodding, C., White, J., & Ryan, P. (2000). Changes in alcohol history taking and management of alcohol dependence by interns at The Royal Adelaide Hospital. Medical Education, 34(3), 170-174.
DOI Scopus8 WoS7 Europe PMC6
1999 Chan, R., Irvine, R., & White, J. (1999). Cardiovascular changes during morphine administration and spontaneous withdrawal in the rat.. European Journal of Pharmacology, 368(1), 25-33.
DOI Scopus24 WoS24 Europe PMC18
1998 Irvine, R., White, J., & Chan, R. (1998). The influence of restraint on blood pressure in the rat. Journal of Pharmacological and Toxicological Methods, 38(3), 157-167.
DOI Scopus129 WoS120 Europe PMC102
1998 Foster, D. J. R., Somogyi, A. A., White, J., Dyer, K. R., & Bocher, F. (1998). Pharmacokinetics of (R)- and (S)-methadone in methadone maintenance population. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 358(1), R461.
1997 White, J., & Taverner, D. (1997). Drug-seeking behaviour. Australian Prescriber, 20(3), 68-70.
DOI Scopus5
1996 Ryan, C. F., & White, J. M. (1996). Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction, 91(1), 39-45.
DOI Scopus116 WoS104 Europe PMC76
1994 Humeniuk, R. E., White, J. M., & Ong, J. (1994). The effects of GABAB ligands on alcohol withdrawal in mice. Pharmacology Biochemistry and Behavior, 49(3), 561-566.
DOI Scopus25 WoS20 Europe PMC16
1993 Humeniuk, R. E., White, J. M., & Ong, J. (1993). The role of GABAB receptors in mediating the stimulatory effects of ethanol in mice. Psychopharmacology, 111(2), 219-224.
DOI Scopus40 WoS38 Europe PMC29

Year Citation
2023 Gerber, C., Jaunay, E. L., Simpson, B. S., & White, J. M. (2023). Moving beyond wastewater analysis toward epidemiology. In M. Dehghani (Ed.), Source details - Title: Wastewater-Based Epidemiology for the Assessment of Human Exposure to Environmental Pollutants (pp. 33-60). UK: Academic Press.
DOI Scopus1
2020 Beardsley, P. M., Brands, B., Ekwere, I. T., Elliott, S., Jain, R., Kaduri, P., . . . White, J. (2020). WHO Expert Committee on Drug Dependence Forty-second report. In WHO EXPERT COMMITTEE ON DRUG DEPENDENCE: FORTY-SECOND REPORT (Vol. 1026, pp. 34 pages). WORLD HEALTH ORGANIZATION.
2017 Todd, G., & White, J. M. (2017). The long-lasting effects of cannabis use on movement and brain regions that control movement. In V. R. Preedy (Ed.), Source details - Title: Handbook of cannabis and related pathologies (pp. 372-378). United Kingdom: Academic Press.
DOI Scopus1
2016 Pearson Dennett, V., Wilcox, R. A., White, J. M., & Todd, G. (2016). Movement dysfunction as a neuropathology of illicit stimulant abuse. In V. R. Preedy (Ed.), Source details - Title: The neuropathology of drug addictions and substance misuse volume 3: general processes and mechanisms, prescription medications, caffeine and areca, polydrug misuse, emerging addictions and non-drug addictions (Vol. 3, pp. 219-228). UK: Elsevier.
DOI Scopus1
2010 White, J., & Lintzeris, N. (2010). Psychopharmacology. In Addiction Research Methods (pp. 221-234). Wiley.
DOI Scopus2
2009 Lintzeris, N., Clark, N., Muhleisen, P., Ritter, A., Ali, R., Bell, J., . . . White, J. (2009). National clinical guidelines and procedures for the use of buprenorphine in the treatment of heroin dependence. In R. Mattick, R. Ali, & N. Lintzeris (Eds.), Pharmacotherapies for the Treatment of Opioid Dependence: Efficacy, Cost-Effectiveness and Implementation Guidelines (pp. 390-445). New York, USA: Informa.
2009 Bell, J., Kimber, J., Lintzeris, N., White, J., Monheit, B., Henry-Edwards, S., . . . Quigley, A. (2009). Clinical guidelines and procedures for the use of naltrexone in the management of opioid dependence. In R. Mattick, R. Ali, & N. Lintzeris (Eds.), Pharmacotherapies for the Treatment of Opioid Dependence: Efficacy, Cost-Effectiveness and Implementation Guidelines (pp. 446-474). New York, USA: Informa.
2009 Henry-Edwards, S., Gowing, L., White, J., Ali, R., Bell, J., Brough, J., . . . Quigley, A. (2009). Clinical guidelines and procedures for the use of methadone in the maintenance treatment of opioid dependence. In R. Mattick, R. Ali, & N. Lintzeris (Eds.), Pharmacotherapies for the Treatment of Opioid Dependence: Efficacy, Cost-Effectiveness and Implementation Guidelines (pp. 354-389). New York, USA: Informa.
2009 Gordon, A., Hutchinson, M., La Vincente, S., Mitchell, T., Morrish, G., Newcombe, D., . . . White, J. (2009). Pharmacology of opioid agonists and antagonists. In R. Mattick, R. Ali, & N. Lintzeris (Eds.), Pharmacotherapies for the Treatment of Opioid Dependence: Efficacy, Cost-Effectiveness and Implementation Guidelines (pp. 15-53). New York, USA: Informa.
2009 Clark, A., Gijsbers, A., & White, J. M. (2009). LAAM in the treatment of opioid dependence:A systematic review. In R. P. Mattick, R. Ali, & N. Lintzeris (Eds.), Source details - Title: Pharmacotherapies for the Treatment of Opioid dependence; Efficacy, Cost-Efectiveness, and Implementation Guidelines (pp. 142-192). US: Informa Healthcare.
2007 White, J., & Hay, J. (2007). Opioids, pain and addiction: Cause and consequence. In P. Miller, & D. Kavanagh (Eds.), Translation of Addictions Science Science into Practice (pp. 39-55). Oxford, UK: Elsevier.
DOI Scopus2

Year Citation
2019 Gerber, C., Nguyen, L., Bade, R., White, J., Tscharke, B., O'Brien, J., . . . Thomas, K. (2019). Measuring the scale of opioid consumption in Australia by wastewater analysis. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 258 (pp. 1 page). CA, San Diego: AMER CHEMICAL SOC.
2010 White, J., Irvine, R., Kostakis, C., Felgate, P., Jaehne, E., Zuccato, E., & Fanelli, R. (2010). International differences in stimulant use: Comparison of cocaine, methamphetamine and MDMA using wastewater analysis. In INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY Vol. 13 (pp. 7). Hong Kong, PEOPLES R CHINA: CAMBRIDGE UNIV PRESS.
WoS1
2009 Newcombe, D., & White, J. (2009). COGNITIVE FUNCTION IN PATIENTS UNDERGOING OPIOID AGONIST MAINTENANCE TREATMENT AND CONTROL SUBJECTS. In DRUG AND ALCOHOL REVIEW Vol. 28 (pp. A47). WILEY-BLACKWELL PUBLISHING, INC.
2004 Srisurapanont, M., McGregor, C., Jittiwutikarn, J., Laobhripatr, S., Wonttan, T. I., & White, J. (2004). Nature, time course and severity of acute methamphetamine withdrawal. In INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY Vol. 7 (pp. S139). Paris, FRANCE: CAMBRIDGE UNIV PRESS.

Year Citation
2013 Hotham, E., Ali, R., White, J., & Robinson, J. (2013). CONDUCTING RESEARCH WITH PREGNANT SUBSTANCE USERS: SOME CONSIDERATIONS. Poster session presented at the meeting of DRUG AND ALCOHOL REVIEW. WILEY-BLACKWELL.

Year Citation
2024 Tscharke, B., Verhagen, R., Bade, R., O'Brien, J., Prasad, P., Barry, D., . . . Gerber, C. (2024). National Wastewater Drug Monitoring Program - report 23. Australia: Australian Criminal Intelligence Commission.
2024 Tscharke, B., Verhagen, R., Bade, R., O'Brien, J., Prasad, P., Barry, D., . . . Gerber, C. (2024). National Wastewater Drug Monitoring Program: report 22. Australia: Australian Criminal Intelligence Commission.
2024 Tscharke, B., Bade, R., O'Brien, J., Prasad, P., Barry, D., Elisei, G., . . . Gerber, C. (2024). National wastewater drug monitoring program report 21. Australia: Australian Criminal Intelligence Commission.
2023 Tscharke, B., O'Brien, J., Bade, R., Prasad, P., Barry, D., Elisei, G., . . . Gerber, C. (2023). National wastewater drug monitoring program Report 20. Australia: Australian Criminal Intelligence Commission.
2023 Tscharke, B., Bade, R., O'Brien, J., Prasad, P., Barry, D., Elisei, G., . . . Gerber, C. (2023). National wastewater drug monitoring program - report 18. Australia: Australian Criminal Intelligence Commission.
2023 Tscharke, B., O'Brien, J., Bade, R., Prasad, P., Barry, D., Elisei, G., . . . Gerber, C. (2023). National wastewater drug monitoring program - report 19. Australia: Australian Criminal Intelligence Commission.
2022 Tscharke, B., Bade, R., O'Brien, J., Reeks, T., Prasad, P., Elisei, G., . . . Gerber, C. (2022). National wastewater drug monitoring program - report 16. Australia: Australian Criminal Intelligence Commission.
2022 Tscharke, B., O'Brien, J., Bade, R., Prasad, P., Barry, D., Elisei, G., . . . Gerber, C. (2022). National wastewater drug monitoring program - report 17. Australia: Australian Criminal Intelligence Commission.
2022 Tscharke, B., O'Brien, J., Bade, R., Reeks, T., Prasad, P., Elisei, G., . . . White, J. (2022). National wastewater drug monitoring program - report 15. Australia: Australian Criminal Intelligence Commission.
2021 Tscharke, B., O'Brien, J., Bade, R., Reeks, T., Prasad, P., Elisei, G., . . . White, J. (2021). National wastewater drug monitoring program - report 14. Australia: Australian Criminal Intelligence Commission.
2019 Tscharke, B., Mackie, R., O'Brien, J., Grant, S., Mueller, J., Ghetia, M., . . . White, J. (2019). National Wastewater Drug Monitoring Program: report 8. Australia: Australian Criminal Intelligence Commission.
2019 Tscharke, B., Mackie, R., O'Brien, J., Grant, S., Mueller, J., Ghetia, M., . . . White, J. (2019). National Wastewater Drug Monitoring Program: report 7. Australia: Australian Criminal Intelligence Commission.
2018 Tscharke, B., Mackie, R., O'Brien, J., Grant, S., Mueller, J., Ghetia, M., . . . White, J. (2018). National Wastewater Drug Monitoring Program: report 6. Australia: Australian Criminal Intelligence Commission.
2018 Tscharke, B., Mackie, R., O'Brien, J., Grant, S., Mueller, J., Ghetia, M., . . . White, J. (2018). National Wastewater Drug Monitoring Program: report 5. Australia: Australian Criminal Intelligence Commission.
2017 Tscharke, B., Mackie, R., O'Brien, J., Grant, S., Mueller, J., Bade, R., . . . White, J. (2017). National wastewater drug monitoring program: report 2. Australia: Australian Criminal Intelligence Commission.
2017 Tscharke, B., Mackie, R., O'Brien, J., Grant, S., Mueller, J., Ghetia, M., . . . White, J. (2017). National Wastewater Drug Monitoring Program: report 3. Australia: Australian Criminal Intelligence Commission.
2017 O'Brien, J., Grant, S., Mueller, J., Tscharke, B., Gerber, C., & White, J. (2017). National Wastewater Drug Monitoring Program: report 1. Australia: Australian Criminal Intelligence Commission.
2017 Tscharke, B., Mackie, R., O'Brien, J., Grant, S., Mueller, J., Ghetia, M., . . . White, J. (2017). National Wastewater Drug Monitoring Program: report 4. Australia: Australian Criminal Intelligence Commission.

  • Randomised double-blind placebo-controlled study of lisdexamfetamine for the treatment of methamphetamine dependence, NHMRC - Project Grant, 01/01/2016 - 31/12/2021

  • Daily sampling at an agreed South Australian regional wastewater treatment plant, Australian Criminal Intelligence Commission, 15/03/2021 - 30/06/2021

  • Prison Wastewater Sampling and Analysis, SA Dept for Correctional Services, 11/08/2020 - 07/02/2021

  • Tracking use of novel psychoactive substances in Australia, Thyne Reid Foundation Grant, 20/06/2017 - 31/01/2020

  • National Waste Water Analysis Pilot, Australian Criminal Intelligence Commission, 01/01/2017 - 30/12/2019

  • Are young adults aware of the long-lasting consequences of methamphetamine ('ICE') use on all health & would knowledge of a visible long-lasting consequence decrease use of the drug?, Fay Fuller Foundation, 06/03/2017 - 30/06/2019

  • Waste water analysis to test methamphetamine usage levels, Western Australia Police, 01/08/2015 - 02/08/2018

  • Research Infrastructure Fund (RIF) Grant 2016 Round 2 - Biofilm Testing Facility, Adelaide Integrated Bioscience Laboratories, 28/11/2016 - 31/12/2017

  • Waste water analysis to test metabolites of a variety of drugs, Southern Adelaide Health Service, 01/10/2015 - 18/12/2017

Date Role Research Topic Program Degree Type Student Load Student Name
2009 - 2013 External Supervisor Illicit stimulant use in the population monitored by wastewater analyses Doctor of Philosophy Doctorate Full Time Mr Chang Chen
2007 - 2010 External Supervisor Antidepressant-like Effects of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Doctor of Philosophy Doctorate Full Time Miss Irina Majumder
2006 - 2013 External Supervisor The Effect of Opioids on Emotional Reactivity Doctor of Philosophy Doctorate Full Time Mr Steven Savvas
2004 - 2010 Co-Supervisor Investigation of the Alcohol, Smoking and Substance Involvement Screening Test (The ASSIST) in Pregnancy Doctor of Philosophy Doctorate Part Time Ms Elizabeth Dorothy Hotham
2003 - 2007 Principal Supervisor Evaluation and Treatment of Opioid-Induced Hyperalgesia Doctor of Philosophy Doctorate Full Time Mr Justin Hay
2002 - 2006 Co-Supervisor Buprenorphine and Methadone in Pregnancy: Effects on the Mother, Fetus and Neonate Doctor of Philosophy Doctorate Full Time Dr Andrea Pelentsov
2002 - 2007 Principal Supervisor Clinical Pharmacology of Methadone Induction Doctor of Philosophy Doctorate Part Time Ms Erin Morton
2001 - 2005 Principal Supervisor ENHANCING THE USE OF OPIOIDS IN PAIN MANAGEMENT: ANTINOCICEPTIVE POTENTIATION WITH OPIOID AGONIST/ANTAGONIST COMBINATIONS Doctor of Philosophy Doctorate Full Time Dr Sophie La Vincente
2001 - 2005 Principal Supervisor Amphetamine Withdrawal: Nature, Time Course and Treatment Doctor of Philosophy Doctorate Full Time Ms Catherine Mc Gregor
2001 - 2013 External Supervisor Opioid Maintained Subjects and the Effects of High Dose Morphine and Adjuvant Analgesics Doctor of Philosophy Doctorate Full Time Mr Peter-Allan Athanasos
2000 - 2004 Principal Supervisor A comparison of methadone and slow-release oral morphine as maintenance pharmacotherapies for opioid dependence Doctor of Philosophy Doctorate Full Time Mr Timothy Mitchell
1998 - 2002 Principal Supervisor ACUTE PAIN MANAGEMENT IN METHADONE MAINTENANCE TREATMENT Doctor of Philosophy Doctorate Full Time Mr Mark Doverty
1997 - 2001 Principal Supervisor THE PREVALENCE AND ROLE OF ALCOHOL, MARIJUANA, BENZODIAZEPINES AND STIMULANTS IN DRIVERS INJURED IN ROAD CRASHES Doctor of Philosophy Doctorate Part Time Ms Maria Longo
1997 - 2006 Principal Supervisor An Examination of the Pharmacodynamics and Pharmacokinetics of Levo-alpha-acetylmethadol (LAAM), compared to Methadone, in Opioid Maintenance Patients Doctor of Philosophy Doctorate Full Time Mr David Newcombe

Connect With Me

External Profiles

Other Links